Tiziana Life Sciences Ltd.: Tiziana Life Sciences Files for Orphan Drug Designation with the FDA for Intranasal Foralumab for the Treatment of Multiple System Atrophy (MSA)1 report from 1 outlet in 1 language · first reported 2026-09-30 11:25 UTC · updated 2026-09-30 11:25 UTC · JSONHealthUnited States Food and Drug AdministrationForalumabmultiple system atrophyReportsTiziana Life Sciences Ltd.: Tiziana Life Sciences Files for Orphan Drug Designation with the FDA for Intranasal Foralumab for the Treatment of Multiple System Atrophy (MSA)finanznachrichten.de · en · 2026-09-30 11:25 UTC